Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS - Wikidata - awgldk - TriplyDB

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

http://www.wikidata.org/entity/Q34023414

about

The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger.Ready or not? Lung cancer diagnosis in 2015.BMP4 depletion by miR-200 inhibits tumorigenesis and metastasis of lung adenocarcinoma cells.Anti-cancer effect of snake venom toxin through down regulation of AP-1 mediated PRDX6 expression TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions.Clinicopathological features and relation between anaplastic lymphoma kinase (ALK) mutation and histological subtype of lung adenocarcinoma in Eastern European Caucasian population.RYBP Inhibits Progression and Metastasis of Lung Cancer by Suppressing EGFR Signaling and Epithelial-Mesenchymal Transition.MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling.Noninvasive Bioluminescence Imaging of AKT Kinase Activity in Subcutaneous and Orthotopic NSCLC Xenografts: Correlation of AKT Activity with Tumor Growth Kinetics.Application of clinical bioinformatics in lung cancer-specific biomarkers.A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.P21, COX-2, and E-cadherin are potential prognostic factors for esophageal squamous cell carcinoma.Regulation of expression of microRNAs by DNA methylation in lung cancer.Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.CHKA mediates the poor prognosis of lung adenocarcinoma and acts as a prognostic indicator.Serum neuron specific enolase levels correlate with patient prognosis for advanced lung cancer.Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants.Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer.The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine.Tyro3-mediated phosphorylation of ACTN4 at tyrosines is FAK-dependent and decreases susceptibility to cleavage by m-Calpain.Detection of Promoter DNA Methylation of APC, DAPK, and GSTP1 Genes in tissue Biopsy and Matched Serum of Advanced-Stage Lung Cancer Patients.Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ.Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology.An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Cav3.1 overexpression is associated with negative characteristics and prognosis in non-small cell lung cancer.Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancer.Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.Genotyping of EGFR Mutations from Bronchial Cytological Specimens in Slovakian Lung Cancer Patients.[The Current Immunohistochemistry Markers in the Resected Tissues of Non-small Cell Lung Cancer Could Not Predict Prognosis].

P2860

Q26741041-797BEAC4-5F4E-4D24-ACDD-984E2EAA1903 Q28077504-44DFFA81-A820-45C6-837F-04AE0396AA9B Q33735646-D4F25D0A-D35C-4F75-B287-A65DC2219F58 Q33757138-E205B7DD-5585-460A-BE2D-0C911355963B Q35632206-105CF037-3EF0-4177-839D-5D000CB76F0C Q35762477-5A771F6F-14F1-48C2-A4DE-E83405BF21BB Q35934215-F2DDD0D1-3F93-4DC9-B0FE-AB81ED151F73 Q36086181-7CA241C9-7FB3-4831-BF96-2A69D0C1F698 Q36355898-91261CBE-9091-4807-B603-F8F0F2C1F030 Q37388699-B52EF4B0-79DB-4A49-B2D4-96B073D95BEA Q37514055-3C6F3E60-E51A-4C4C-99B7-26FBDEB27EE7 Q37672584-03FBD83A-1849-4CB1-BAF6-2986065186B3 Q37718370-E629E360-1CE3-4F24-9A23-7C47E9549242 Q37719572-FD454DC1-422D-4213-B5CB-56705A2C8C2E Q37736706-422F6BC2-A69F-401C-B0D3-7F21F333CE4F Q38453827-3C1D3D67-632E-40CD-831B-54D7948745D5 Q38599094-946BF96D-135D-472F-A138-A5C9D54F75ED Q38731759-FA397DE1-8FDC-4500-AD7C-50E0DD923C87 Q38792903-043804E7-AF6C-4B3A-9DF0-B1746B5891D6 Q38819457-E402FB4D-0A36-4942-B285-C0A98005B875 Q38937135-00D79075-45C9-4F6A-B00E-96AB1ACF001F Q40070868-63F622D7-494B-4F64-B851-55D503C7A678 Q41108912-48EFB0FF-A553-4DEA-B34D-03485B95048A Q41174483-77086A43-79E1-4280-A972-1E91837B0C18 Q42267604-465C35D6-D496-428C-B710-36489B5912E2 Q42276714-84BBAD43-173A-42CA-88F1-B5CFCA81A9A1 Q42323049-C84681D6-FE8D-4F7B-87B0-20B818421CB2 Q42340129-826AEAC9-1D30-4745-887C-5BC65FACBA59 Q42378386-1ECC06D6-2906-4D03-B197-57A3D0D49175 Q43128868-A4BF6B34-F982-4F12-9D60-76C077D87EE9 Q47222376-F77DA800-908B-4A44-9C88-CCF5C435C4BD Q47729297-F2B64C85-2170-4756-9671-1F2CEB4D2FEB Q48214345-89F2098E-70E8-49A6-A546-C7FFDDE6BFD7 Q48536576-D947C6D2-EA85-4F00-9201-9D26CFC9DFB4 Q49667322-A9DB735D-570D-4171-A573-18ADB06D54EE Q50328652-ABDEB619-7CCA-43C9-BFFE-7FA743115C9A Q50654488-A198B75D-2E91-46BA-94AD-493F3AA39C68 Q52566930-B812C330-747B-4B42-B422-821059CF7E8C Q52867018-1CAEB801-D49C-4ABC-9480-C02E7127A19D Q53204318-78E6CC9D-0C78-4816-B8CE-BCD2A27AB67E

P2860

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

http://www.wikidata.org/entity/Q34023414

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Biomarkers That Currently Affe ...... GFR, ALK, MET, ROS-1, and KRAS

@ast

Biomarkers That Currently Affe ...... GFR, ALK, MET, ROS-1, and KRAS

@en

Biomarkers That Currently Affe ...... GFR, ALK, MET, ROS-1, and KRAS

@nl

type

label

Biomarkers That Currently Affe ...... GFR, ALK, MET, ROS-1, and KRAS

@ast

Biomarkers That Currently Affe ...... GFR, ALK, MET, ROS-1, and KRAS

@en

Biomarkers That Currently Affe ...... GFR, ALK, MET, ROS-1, and KRAS

@nl

prefLabel

Biomarkers That Currently Affe ...... GFR, ALK, MET, ROS-1, and KRAS

@ast

Biomarkers That Currently Affe ...... GFR, ALK, MET, ROS-1, and KRAS

@en

Biomarkers That Currently Affe ...... GFR, ALK, MET, ROS-1, and KRAS

@nl

P1433

Q34023414-B04051A3-AD09-434D-8A1F-DD25C264A922

P1476

Q34023414-AEA16CD3-E433-477B-A608-B7776730CDF7

P2093

Q34023414-204F8840-6AD8-4AA3-BD5C-DDBC0575A90E

Q34023414-21528000-43B8-4DA7-987D-FF346843C44A

Q34023414-2B1DD754-3D83-410D-ADD5-C379F9BA8219

Q34023414-C003D65D-9EC0-422C-BD90-FA68AE127B1A

P2860

Q34023414-05A05FB4-39B2-4114-AF1A-953CA4D6A3C5

Q34023414-0836E67E-6E9F-4611-B8EE-300889257F19

Q34023414-0ACB10BD-2968-4066-81D9-6C7F20D8B85B

Q34023414-0CC0A4CE-201D-407C-BD58-52814520EB08

Q34023414-0E234F95-6ADA-4DC9-9106-528382110FB3

Q34023414-1008254E-BA49-4C7F-9B88-E37608418A48

Q34023414-10894F23-4273-48FD-800D-04D92D83098C

Q34023414-11901B7F-F170-489E-A80B-C896053CE55D

Q34023414-12148504-E08C-4949-8932-5C42DB85E353

Q34023414-1492579D-42DA-4CDE-A0E9-D126A47C7B26

P304

Q34023414-D544FF0F-17AC-44BB-8B36-6D83E562D33B

P31

Q34023414-8D033D2D-595B-4D53-BCF7-D6F6082B1312

P356

Q34023414-885418A2-C944-451E-92CF-CD616C5156D4

P478

Q34023414-E502FAFE-DA00-4555-83F4-3547B00ED74D

P577

Q34023414-1BC187BF-356A-4564-948E-89FE4C66D53E

P5875

Q34023414-2019A017-3AAB-49D0-93BA-62236BD49D19

P698

Q34023414-41DD32C6-D513-4F00-9A03-3C2E65431816

P921

Q34023414-E4036BE7-92E2-482D-9942-96274F3221F4

P932

Q34023414-E403B45A-8A84-49F1-A036-72C1C3090D34

P356

FONC.2014.00204

P1433

Frontiers in Oncology

P1476

Biomarkers That Currently Affe ...... GFR, ALK, MET, ROS-1, and KRAS

@en

P2093

Donna M Graham

http://www.w3.org/2001/XMLSchema#string

Grzegorz J Korpanty

http://www.w3.org/2001/XMLSchema#string

Mark D Vincent

http://www.w3.org/2001/XMLSchema#string

Natasha B Leighl

http://www.w3.org/2001/XMLSchema#string

P2860

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Expression and rearrangement of the ROS1 gene in human glioblastoma cells

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

P304

204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2014.00204

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265056589

http://www.w3.org/2001/XMLSchema#string

P698

25157335

http://www.w3.org/2001/XMLSchema#string

P921

P932

4127527

http://www.w3.org/2001/XMLSchema#string